Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Trefoil factors (TFFs) gene expression was analyzed in publicly available cancer genome datasets, followed by assessment of their expression in genetically engineered spontaneous mouse model (GEM) of PC (KrasG12D; Pdx1-Cre (KC)) and in human tissue microarray consisting of normal pancreas adjacent to tumor (NAT), precursor lesions (PanIN), and various pathological grades of PC by immunohistochemistry (IHC).
|
30956167 |
2019 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The ROC curves indicate a sensitivity and specificity of 80% for PDX1 and 86% for MSX2.Gene expression of MSX2 in tissue samples obtained by EUS-FNA and serum expression of MSX2 and PDX1 were higher in patients with PC.
|
31261501 |
2019 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Experiments were performed in a genetically engineered mouse model of pancreatic cancer (KPC mice: LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre).
|
28715967 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx-1-Cre (KPC) mouse model represents an established and frequently used transgenic model to evaluate novel therapies in pancreatic cancer.
|
29683461 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras<sup>G12D/+</sup>;Tp53<sup>R172H/+</sup> (KPC) mice, a genetically engineered model of pancreatic cancer.
|
30306263 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer.
|
29309817 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We utilized human tissue microarrays and different PC mouse models (Pdx1-cre; LSL- Kras<sup>(G12D)</sup>, Pdx1-Cre; LSL-Kras<sup>(G12D)</sup>; LSL-p53<sup>(R172H)</sup> and RIP1-Tag2) to analyze SEMA5A expression during PC progression.
|
29464045 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with metformin also suppressed tumor growth, invasion and EMT in LSL‑KrasG12D/+, Trp53fl/+and Pdx1‑Cre (KPC) transgenic mice that harbor spontaneous pancreatic cancer.
|
29956804 |
2018 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In all but two patients with pancreatic cancer, PDX-1 was expressed and was found positive in 7 patients with pancreatic cancer in which cytology was negative.
|
25454709 |
2015 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PDX1 is overexpressed in pancreatic cancer, and activates the insulin promoter (IP).
|
25596375 |
2015 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, expression of miR-146a in eight PC cell lines, and in pancreatic tissues obtained from transgenic mouse models of K-Ras (K), Pdx1-Cre (C), K-Ras;Pdx1-Cre (KC) and K-Ras;Pdx1-Cre;INK4a/Arf (KCI), showed down-regulation of miR-146a expression in KCI mice which was in part led to over-expression of its target gene, epidermal growth factor receptor (EGFR).
|
24839931 |
2014 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our aim is to review the process of identifying PDX1 as a specific, potential RNAi target in pancreatic cancer, as well as the underlying mechanisms and various forms of RNAi, with subsequent testing and development of PDX1-targeted bifunctional shRNA therapy.
|
24457987 |
2014 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.
|
25086665 |
2014 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer.
|
23828595 |
2013 |
Malignant neoplasm of pancreas
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we have evaluated stage specific expression patterns of mucins during mouse PC progression in (Kras(G12D);Pdx1-Cre (KC)) murine PC model from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) by immunohistochemistry and quantitative real-time PCR.
|
23102107 |
2012 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
PDX-1: demonstration of oncogenic properties in pancreatic cancer.
|
20886630 |
2011 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
CTD_human |
The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer.
|
19077462 |
2009 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of PDX-1 expression inhibits pancreatic cancer cell growth in vitro and in vivo, implying its use as a potential therapeutic target for the treatment of pancreatic cancer.
|
18665085 |
2008 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
To further explore the oncogenic activity of Aurora A kinase while attempting to develop a useful mouse model for pancreatic cancer, Aurora A kinase was targeted to pancreatic duodenal homeobox gene-1 (Pdx-1)-positive cells.
|
18815537 |
2008 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 co-delivery.
|
17161985 |
2007 |
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, PDX-1 protein was found in all six freshly isolated human pancreas cancer specimens and two liver metastasis samples that were group-tested, suggesting the feasibility of using RIP-TK gene therapy in humans.
|
15457366 |
2004 |
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, two freshly isolated human pancreatic cancer specimens had significantly increased levels of PDX-1.
|
14746841 |
2004 |